Ignite Creation Date:
2025-12-24 @ 7:48 PM
Ignite Modification Date:
2026-03-11 @ 5:24 PM
Study NCT ID:
NCT03029403
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-09-19
First Post:
2017-01-20
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Sponsor:
University Health Network, Toronto
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-02-12
Start Date Type:
ACTUAL
Primary Completion Date:
2025-12-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-04-12
Completion Date Type:
ESTIMATED
First Submit Date:
2017-01-20
First Submit QC Date:
None
Study First Post Date:
2017-01-24
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-09-15
Last Update Post Date:
2025-09-19
Last Update Post Date Type:
ESTIMATED